Eli Lilly’s weight loss injection Zepbound and diabetes drug Mounjaro are now fully available in the U.S., as stated in an update on the U.S. Food and Drug Administration’s drug shortage database. This update marks a significant development in the availability of these popular medications. Previously, there were shortages reported for some doses of these treatments, causing concern among patients and healthcare providers.
The shortage of Mounjaro dates back to as early as 2022, while Zepbound joined the list of drugs in short supply earlier this year after receiving approval in the U.S. The high demand for weight loss and diabetes drugs has surpassed the available supply for months, prompting companies like Eli Lilly and Novo Nordisk to invest substantial amounts of money into increasing their manufacturing capabilities.
Expectations from Eli Lilly CEO
In an interview with Bloomberg, Eli Lilly CEO David Ricks expressed optimism about the end of shortages for Mounjaro and Zepbound. He mentioned that the company plans to resolve the supply issues “very soon,” indicating a positive outlook for patients who rely on these medications for their health management. However, a spokesperson for Eli Lilly did not provide immediate comments on the FDA’s update regarding the drug availability.
In addition to Eli Lilly’s medications, all doses of Novo Nordisk’s diabetes injection Ozempic are also readily available in the U.S., as confirmed by the FDA’s database. However, the FDA reported that there are limited supplies of Novo Nordisk’s weight loss drug Wegovy. This information suggests that while some companies have managed to resolve supply issues, others are still facing challenges in meeting the demand for certain medications.
The availability of Eli Lilly’s weight loss injection and diabetes drug in the U.S. has improved significantly, with all doses now accessible to patients. The efforts made by pharmaceutical companies to address shortages and ramp up production have resulted in better access to essential medications for those in need. Moving forward, it will be essential for companies to continue monitoring supply chains and addressing any bottlenecks to ensure consistent availability of these vital drugs.